Edition:
United States

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

10.07EUR
5 Dec 2016
Change (% chg)

€0.24 (+2.44%)
Prev Close
€9.84
Open
€9.93
Day's High
€10.10
Day's Low
€9.84
Volume
206,394
Avg. Vol
214,519
52-wk High
€16.20
52-wk Low
€8.21

Summary

Name Age Since Current Position

Peter Fellner

72 2013 Chairman of the Board

Edwin Moses

61 2013 Chief Executive Officer, Director

Wim Ottevaere

59 Chief Financial Officer

Kim Simonsen

42 Chief Operations Officer

Antonin de Fougerolles

2013 Chief Scientific Officer

Frank Landolt

Vice President - Intellectual Property, and Legal

Guido Gielen

Vice President - Human Resources

Johan Heylen

2014 Chief Commercial Officer

Dominique Tersago

2013 Chief Medical Officer

Russell Greig

64 Independent Director

Bo Hansen

58 Independent Director

William Jenkins

67 Independent Director

Catherine Moukheibir

57 Independent Director

Lutgart Van den Berghe

64 Independent Director

Remi Vermeiren

75 Independent Director

Biographies

Name Description

Peter Fellner

Dr. Peter J. Fellner, Ph.D., is Chairman of the Board of Directors of Ablynx NV. since 2013. He is currently Chairman of the Boards of Consort Medical plc and Optos plc. In addition, he serves as Chairman of the biotech company Vernalis plc. He was recently Vice Chairman of Astex Pharmaceuticals Inc, which was acquired in 2013 by Otsuka Pharmaceuticals for US$886 million. He also served as Chairman of Biotie Therapies Corp. from 2010 to 2014, and as a Director of the global biopharmaceutical company UCB from 2005 to 2014, where he continues as a member of the UCB Science Advisory Board. In addition, he is a member of the Novo A/S Advisory Group. Dr Fellner previously served as Chairman of Acambis from 2006 until its acquisition by Sanofi Aventis in 2008, and of Premier Research Group from 2007 to 2008, when it was acquired by a private-equity backed group. He was Chairman of Celltech Group from 2003 to July 2004, until its acquisition for €2.3 billion by UCB, having been CEO from 1990 onwards, during which time he oversaw the Company’s growth from a small research-based company to UK’s largest biotech company. Before joining Celltech, he was CEO of Roche UK from 1986 to 1990. He was nominated Chairman of the Board of Ablynx on 12 November 2013.

Edwin Moses

Dr. Edwin Moses, Ph.D., is Chief Executive Officer, Director of Ablynx NV. After completing his post-doctoral research in Germany, Dr Edwin Moses began a successful commercial career at Amersham International, Enzymatix and Raggio-Italgene. From 1993-2001, first as CEO and later as Chairman, he was responsible for the growth of Oxford Asymmetry (OAI) through a series of venture rounds cumulating in a flotation (LSE) in 1998 at a value of £120 million. This was followed by a sale of the company to Evotec Biosystems in 2000 for £316 million. During this period, OAI grew from four people to over 250. Over the past fourteen years, Edwin has played an important role at Board level (primarily as Chairman) in over 15 European life science companies. During this time he has been involved in a number of financing rounds, a series of M&A transactions and four IPOs. He has been Chairman of Ablynx from 2004 till 2013, and in 2006 he was appointed Chief Executive Officer of the Company. Apart from and in addition to his duties as CEO of the Company, Edwin Moses is the Chairman of the Board of Capricorn Health-tech Fund (Belgium). Furthermore, in addition to Ablynx, he has held Board memberships with the following companies: Clinphone Group plc (UK), Fusion IP plc (formerly Biofusion plc) (UK), Phoqus Pharmaceuticals Ltd (UK), Pharmaceutical Profiles Ltd (UK), Proimmune Ltd (UK), Paradigm Therapeutics Ltd (UK), Avantium Technologies (the Netherlands), Ionix Pharmaceuticals Ltd (UK), Evotec OAI AG (Germany), Bioimage A/S (Denmark), Inpharmatica Ltd (UK), Prolysis Ltd (UK), ProPharma Ltd (UK), Lectus Therapeutics Ltd. (UK) and European Biopharmaceutical Enterprises.

Wim Ottevaere

Mr. Wim Ottevaere is Chief Financial Officer of Ablynx NV. since 2006. He holds a Masters degree in Business Economics from Universiteit Antwerpn, Belgium. From 1978 until 1989, he held various positions in finance and administration within the Dossche group. From 1990 until 1992, he served as Finance Director of Vanhout, a subsidiary of the Besix group, a construction enterprise in Belgium. From 1992 until July 2006, he was Chief Financial Officer of Innogenetics, a biotech company listed on Euronext. He joined the Company in August 2006.

Kim Simonsen

Mr. Kim Simonsen is Chief Operations Officer of Ablynx NV. He received a Doctorate of Medicine degree from the University of Copenhagen and had clinical training for five years before moving into the pharmaceutical industry. He has experience within the field of particularly Clinical Drug Development in the European Union, the United States, Japan and China in different therapeutic areas. He has worked with Sandoz, Novo Nordisk, Novartis, Medicon (a CRO) and as Vice President for Global Clinical Development at ALK-Abello before moving to the Company. He has been given lectures in Clinical Pharmacology and Drug Development in Denmark, within the Association of the Pharmaceutical Industry in Denmark and at Copenhagen and Aalborg University.

Antonin de Fougerolles

Dr. Antonin (Tony) de Fougerolles, Ph.D., is Chief Scientific Officer of Ablynx NV. since October 2013. He has more than 15 years of biotech research and development experience and knowledge in building out pipelines and expanding platform technologies. Prior to joining the Company, he was Chief Scientific Officer at Moderna Therapeutics where he led the Science Department. Previously, he was Chief Scientific Officer at Tolerx Incand, and prior to that he served on the management team of Alnylam Pharmaceuticals as Vice President, Research, Immunology, Metabolic, and Viral Disease from 2003 to 2010. He also served as a Principal Scientist at Biogen, Inc. (now Biogen Idec Inc.) from 1998 to 2003, where he worked on several immunology/inflammation-based programs and led research teams working to develop antibody-based therapeutics. He earned his Doctorate in Philosophy degree in Immunology from Harvard University, and was an Arthritis and Rheumatism Council Research Fellow at the Laboratory of Molecular Biology in Cambridge, England.

Frank Landolt

Mr. Frank Landolt is Vice President - Intellectual Property, and Legal of Ablynx NV. He is a Dutch and European patent Attorney and transactional Lawyer who joined the Company in 2004. He started his career in private practice in the Netherlands, where his clients included pharmaceutical companies, as well as some biotech companies and research institutions in the Netherlands. From 2000 to 2004, he was Director of Intellectual Property and Legal at Devgen, another Belgian biotech company. He holds a degree in Chemistry from Universiteit Leiden, a degree in Civil Law from Universiteit Leiden, and a degree in Business Law from Universiteit Antwerpen.

Guido Gielen

Mr. Guido Gielen is Vice President - Human Resources of Ablynx NV. He obtained a Masters degree in Sociology from Katholieke Universiteit Leuven. Prior to his position at the Company, he held several local and international human resources positions within Johnson & Johnson from 1990 to 2010. During this period, he worked with client groups in Operations, General Services, Sales and Marketing and Research and Development in Western Europe, Central and Eastern Europe, the United States and Asia.

Johan Heylen

Mr. Johan Heylen is Chief Commercial Officer of the company. He has more than 20 years of experience in global biopharmaceutical sales, marketing and business development at GlaxoSmithKline (GSK), Servier and Wyeth. Most recently, Johan was Executive Director, Global Commercial Lead, Cancer Immunotherapeutics, at GSK, where he headed the global commercial teams and was responsible for the development and implementation of the launch strategy for GSK’s cancer immunotherapeutics portfolio. Prior to that, Johan led and launched the successful global commercial and marketing efforts for three of GSK’s paediatric vaccines, Rotarix, Priorix and Varilrix, which together achieved sales of more than €1.5 billion. He has experience in a wide range of therapeutic fields and regions, having worked and lived in Europe, Latin-America, Asia and most recently in the USA. Johan holds degrees in pharmacy (KUL), economics (VLEKHO) and management (ULB, Solvay Business School and the Stockholm School of Economics). Johan has been guest speaker at congresses and universities throughout Europe on Clinical R&D and Marketing, and is currently lecturer in marketing at the Université Libre de Bruxelles (Pharmed).

Dominique Tersago

Ms. Dominique Tersago is Chief Medical Officer of Ablynx NV. since July 2013. She joined the Company in January 2011 to head the Medical group. Prior to joining the Company, she was Director Regulatory Strategy, Europe with Bristol-Myers Squibb International in the therapeutic areas of oncology and virology. She received her Doctorate of Medicine degree from Universiteit Antwerpen, Belgium. She joined the pharmaceutical industry in 1994 with Janssen Research Foundation (Johnson & Johnson) and has held positions in clinical development and regulatory strategy.

Russell Greig

Dr. Russell G. Greig, Ph.D., is Independent Director of Ablynx NV. He has more than 30 years’ experience in the pharmaceutical industry, with knowledge and expertise in research and development, business development and commercial operations. He spent the majority of his career at GlaxoSmithKline, where he held a number of positions including GSK’s President of Pharmaceuticals International from 2003 to 2008 and Senior Vice President Worldwide Business Development. From 2008 to 2010, Dr Greig was also President of SR One, GSK’s Corporate Venture Group. He is currently Chairman of AM Pharma and Mint Solutions (The Netherlands), a Board Member of Onxeo (France), as well as a Director of Tigenix (Belgium) and Oryzon (Spain). He also acts as Venture Partner to Kurma Life Sciences (France). He served as acting CEO at Genocea and Isconova for an interim period. He was a member of the Scottish Scientific Advisory Committee, reporting to the First Minister. He was also Chairman of Syntaxin (UK), which was acquired by Ipsen (France), Novagali (France) sold to Santen (Japan), and of Isconova (Sweden), acquired by Novavax (USA).

Bo Hansen

Dr. Bo Jesper Hansen, M.D., Ph.D., is Independent Director of Ablynx NV. He is the permanent representative of Orfacare Consulting, currently serves as Executive Chairman of the Board of SOBI AB (Swedish Orphan Biovitrum AB). He is Chairman of Karolinska Development AB and is also non-executive Director of a number of biotech and pharma companies including Orphazyme ApS, Newron Pharmaceuticals SpA, CMC AB, Hyperion Therapeutics Inc. and Genspera Inc. Dr Hansen served as CEO and President and as Director to the Board of Swedish Orphan International until the merger with Biovitrum, forming Swedish Orphan Biovitrum. He also was non-executive Director of Gambro until its acquisition by Baxter, and Zymenex, until its acquisition by Chiesi. Dr. Hansen was the Executive Chairman of Topotarget and in this role led the merger with BioAlliance forming OnXeo. He founded Scandinavian Medical Research during which he served as Medical Advisor for Synthélabo, Pfizer, Pharmacia and Yamanouchi Pharmaceutical.

William Jenkins

Dr. William J. Jenkins, M.D., is Independent Director of Ablynx NV. He is Principal of William Jenkins Pharma Consulting and has been advising a wide range of pharma and biotech companies, and investment and venture capital firms in the healthcare sector since 1999. Formerly, he was Head of Worldwide Clinical and Regulatory Affairs for Novartis Pharma and held a similar position with Glaxo Group Research Limited. He is currently Senior independent Director of Consort Medical, a member of the Board of Allecra Therapeutics AG and of Allocyte Pharmaceuticals AG, and a member of the Strategic Advisory Board of Chiesi Farmaceutici. In addition, he is a member of the Scientific Advisory Boards of BB Biotech Ventures II and III funds, and until recently of Nicholas Piramal India.

Catherine Moukheibir

Ms. Catherine Moukheibir is Independent Director of Ablynx NV. She has been in C-level positions in several European biotech companies after an initial career in strategy consulting and investment banking in Boston and London. Her particular experience lies in aligning corporate and financial strategy appropriate to various stages of a biotech’s development, on the continuum from venture capital funding to public market or M&A. She is currently a non-executive Board member of Creabilis and a Board observer at Zealand Pharma. She is also a member of the three-person management board at Innate Pharma where she is responsible for financial and corporate strategy. Catherine Moukheibir holds an MBA from Yale University.

Lutgart Van den Berghe

Professor. Lutgart A.A. Van den Berghe is Independent Director the company. She is Executive Director of GUBERNA (Belgian Governance Institute) and Extra-Ordinary Professor in Corporate Governance at the University of Ghent (B). She is a Partner of the Vlerick Business School. In the school, she served for many years as Chairman of the Competence Center "Entrepreneurship, Governance and Strategy”. She has an extensive governance experience gained as Member of the Belgian Commission for Corporate Governance and Non-Executive Director in several companies, such as BELGACOM (B) and Belfius (B). At EcoDA (European Confederation of Directors’ Association), she is a Member of the Board and chairwoman of its policy committee. Formerly she served as a non-executive director of Electrabel (B, 2003-2014), the ING Group (NL, 1991-2003), KLM (NL, 2001 - 2004), Solvay (B, 2003-2007), CSM (NL, 1998 - 2010), SHV (NL, 1997-2013), Capco NV (B, 2000 – 2003), DVV (B, 1995 - 1997), member of the Audit Committee of the Flemish Government (B, 2000 – 2004) and Chairman of the Proximus Foundation (until 2005). She was also a Member of the Advisory Board of Lazard (Benelux, 2007 – 2010) Lutgart Van den Berghe is doctor in Business Economics of the University of Gent.

Remi Vermeiren

Mr. Remi Vermeiren is Independent Director of Ablynx NV. He he had a 43 year long career at Kredietbank NV, which in 1998 merged with Cera Bank and ABB Insurance into KBC Bank and Insurance Group. In the earlier years, he was mainly involved in Asset Management, Trading and Administration of Securities, Treasury and International and Investment banking. From 1989 on, he was a member of the Executive Committee responsible for the day-to-day management of the bank. From 1998 until 2003, he held the function of Chairman of the KBC Bank and Insurance Group and of KBC Bank. During this period, he was mainly involved in defining the strategy of the new group, integration of the banking and insurance activities, implementation of the merger of the two banks and the cost reduction going with it, and expansion of KBC into Central Europe where it became one of the most important Western European investors in the banking and insurance industry. Currently, Mr Vermeiren is also member of a number of non-quoted companies and of charitable organisations, such as De Warande, Pro Vives, Vives and ‘Foundation RV’ set up and funded by himself. He is currently a member of the Board or supervisory bodies of the following companies: ACP II SCA (Luxembourg) (Liquidator) and Zinner NV (Belgium). In the past five years, he has held positions as a member of the Board or administrative, management or supervisory bodies of the following companies: Devgen NV (Belgium), Afinia Plastics NV (Belgium), IFB SPA (Italy), Cumerio NV (Belgium) and MCS NV. Remi Vermeiren holds a degree in commercial and financial sciences.